FilingsTodayGilead Sciences
At a glance
Gilead Sciences reported 2025 revenue of $29.44B, up 2.4% from $28.75B in 2024. Over 4 years since 2021 ($27.3B), that is growth of about 1.9% a year. Operating margin was 34%, down from 36.3% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 7 insiders reported 0 open-market purchases and 37 sales ($84.2M). 36 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $17.3M by Chairman & CEO Daniel Patrick O'Day on Feb 6, 2026.
Gilead Sciences filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), material agreement (2), new financial obligation (1) and shareholder vote results (1). The latest officer or director change was reported on Nov 19, 2025. It reported a material agreement or a completed acquisition or disposal 2 times.
3 of the 20 investors tracked here held Gilead Sciences at the last quarter end, worth $703.8M combined. It is the largest weight for Renaissance Technologies (0.4% of its portfolio), followed by National Pension Service (Korea) (0.2%). Added: Renaissance Technologies, National Pension Service (Korea) and Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $6.22B | $4.59B | $5.67B | $480M | $8.51B |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Dividend per share | $2.84 | $2.92 | $3.00 | $3.08 | $3.16 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined